KHẢO SÁT TÌNH HÌNH SỬ DỤNG THUỐC ĐIỀU TRỊ ĐÁI THÁO ĐƯỜNG TÝP 2 Ở BỆNH NHÂN CAO TUỔI NGOẠI TRÚ TẠI BỆNH VIỆN QUÂN Y 175

Nhung Nguyễn Thị Hồng; Anh Nguyễn Thị Bảo; Thùy Đỗ Thị; Hương Lương Thị Thu; Hương Phạm Thị Thu

doi:10.59354/ydth175.2023.227

Keywords:

typ 2 diabetes, antidiabetic drugs, the elderly

Abstract

Background: Diabetes is one of the most frequent chronic metabolic diseases that affects the elderly. This study aims to investigate the use of antihyperglycemic drugs and assess the efficacy after three months of treatment

Methods: A retrospective study of 102 outpatients with typ 2 diabetes, aged 60 years or older, receiving outpatient anti-diabetic drugs for at least 3 months

Results: The median age of 102 patients was 67.5 (64–72) (years). The most three common drugs were metformin (41.2%), gliclazide (16.6%), and sitagliptin (16.1%). 92.2% patients were indicated drugs appropriately. The blood glucose level after 3 months of treatment decreased significantly (p =0.001 < 0.05).

Conclusion: The majority of elderly patients at Military Hospital 175 were treated with a combination of 2 drugs (37.3%). The most commonly used active ingredient is metformin (41.2%). The proportion of patients with good blood glucose control after 3 months of treatment in the entire study sample was 68.6%. The change in blood glucose level at T3 compared to T0 was statistically significant (p = 0.0001 < 0.05).

References

Quyết định 5481/QĐ-BYT ngày 20/12/2020 về việc ban hành tài liệu chuyên môn. Hướng dẫn chẩn đoán và điều trị đái tháo đường típ 2.

Forouhi NG, Wareham NJ. (2019) Epidemiology of diabetes. Medicine (Baltimore);47(1):22–7.

Thông tin y tế trên các trang web Bộ y tế ngày 13/11/2022

https://moh.gov.vn/tin-noi-bat/-/ asset_publisher/3Yst7YhbkA5j/content/ khoang-5-trieu-nguoi-viet-ang-mac-can-benh-gay-nhieu-bien-chung-ve-tim-mach-than-kinh-cat-cut-chi-

Nobili A, Garattini S, Mannucci PM. (2011) Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. J Comorbidity;1:28–44.

Lam TV, Trí NT. Sử dụng thuốc hạ đường huyết điều trị bệnh đái tháo đường típ 2 tại Trung tâm Y tế Thị xã Long Mỹ năm 2020. (2022) Vietnam J Diabetes Endocrinol;(51):64–9.

Warraich HJ, Rana JS. (2017) Dyslipidemia in diabetes mellitus and cardiovascular disease. Cardiovasc Endocrinol;6(1):27–32.

Chen Y hong, Du L, Geng X yuan, Peng Y ling, Shen J ni, Zhang Y gang, và c.s. (2015) Effects of sulfonylureas on lipids in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. J Evid-Based Med;8(3):134–48

Huang CF, Mao TY, Hwang SJ. (2023) The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients. Diabetes Metab Syndr Obes;16:31–6.

Trevisan R. (2017) The Role of Vildagliptin in the Therapy of Type 2 Diabetic Patients with Renal Dysfunction. Diabetes Ther;8(6):1215–26.

Asakura M, Karaki F, Fujii H, Atsuda K, Itoh T, Fujiwara R. (2016) Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cells. Sci Rep;6:35633.